Average one-year price target for Tenax Therapeutics revised to $29.32, up 13.86% from the prior $25.76 estimate dated Feb 21, 2026. This represents a consensus analyst-driven upgrade and signals improved sell-side sentiment for the biotech, likely a modest catalyst rather than a fundamental company development.
Average one-year price target for Tenax Therapeutics revised to $29.32, up 13.86% from the prior $25.76 estimate dated Feb 21, 2026. This represents a consensus analyst-driven upgrade and signals improved sell-side sentiment for the biotech, likely a modest catalyst rather than a fundamental company development.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
